Nature Reviews Drug Discovery 11, 745–746 (2012)
There were some inaccuracies in the description of the compound STX-209 (arbaclofen; Seaside Therapeutics) in the text and table of the article. The compound is currently under Phase IIb clinical investigation for the treatment of the core symptoms of autism spectrum disorders, and it is formulated as an oral rapid disintegrating tablet. This information has been updated in the online version of the article.
Additional information
The online version of the original article can be found at 10.1038/nrd3771
Rights and permissions
About this article
Cite this article
Nightingale, S. Erratum: Autism spectrum disorders. Nat Rev Drug Discov 11, 886 (2012). https://doi.org/10.1038/nrd3892
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3892
This article is cited by
-
A Snapshot of Social Support Networks Among Parental Caregivers of Adults with Autism
Journal of Autism and Developmental Disorders (2020)
